Syngene InternationalNSE:SYNGENE +1.19%86 Gross Margin % is 77.51% as of Mar. 2026, which is 7% above its 10-year median of 72.38. GuruFocus rates NSE:SYNGENE with a GF Score™ of 86/100 and a GF Value™ of ₹768.98 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Syngene International ranks better than 81.54% on this metric.
NSE:SYNGENE's Gross Margin % is ranked better than 81.54% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.31
vs NSE:SYNGENE: 75.43
Syngene International had a gross margin of 77.51% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Syngene International was 0.30% per year.
Syngene International (NSE:SYNGENE) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Syngene International had a gross margin of 77.51% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Syngene International Gross Margin % Related Terms
Syngene International Gross Margin % Historical Data
* Premium members only.
The historical data trend for Syngene International's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SYNGENE vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Syngene International's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngene International Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Syngene International's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Syngene International's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Syngene International (NSE:SYNGENE) has a Gross Margin % of 77.51% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Syngene International and its competitors. This is near median its historical median of 72.38. Over the past decade, Syngene International's Gross Margin % has ranged from 69.03 to 75.43. According to the industry distribution chart, Syngene International ranks #36 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 18.5%.
Is Syngene International's Gross Margin % too high?
Syngene International's current Gross Margin % of 77.51% is near median its 10-year median of 72.38. Over the past 10 years, this metric has ranged from a low of 69.03 to a high of 75.43. The Medical Diagnostics & Research industry median Gross Margin % is 51.31. Syngene International's value of 77.51% is 51.1% above this industry median. Based on the distribution chart, Syngene International ranks #36 out of 195 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Syngene International has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngene International's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Syngene International ranks #36 out of 195 companies for Gross Margin %. This places Syngene International in the top 19% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 51.31. Syngene International's value of 77.51% is 51.1% above this benchmark. Historically, Syngene International's own Gross Margin % has ranged from 69.03 to 75.43 over the past decade. While the company's 10-year median is 72.38 vs. the industry median of 51.31, Syngene International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.31, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syngene International's current Gross Margin % of 77.51% is 51.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Syngene International and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syngene International's current Gross Margin % is 77.51%, which is near median its own 10-year median of 72.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngene International stock overvalued right now?
Based on GuruFocus' analysis, Syngene International (NSE:SYNGENE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹768.98, compared to a current price of ₹420.35 — trading 45.3% below its estimated fair value. The current Gross Margin % is 77.51%, which is near median its 10-year median of 72.38 and 51.1% above the Medical Diagnostics & Research industry median of 51.31. Syngene International's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Syngene International (NSE:SYNGENE), the current Gross Margin % is 77.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngene International (NSE:SYNGENE) Overvalued in 2026?
Based on GuruFocus' analysis, Syngene International stock appears to be undervalued.
The current stock price of ₹420.35 is trading 45.3% below its estimated GF Value™ of ₹768.98.
GuruFocus considers Syngene International to be Significantly Undervalued.
Key valuation signals for NSE:SYNGENE:
Gross Margin %: 77.51% (near median its 10-year median of 72.38)
GF Value™: ₹768.98 vs. price of ₹420.35 (45.3% below fair value)
Industry Position: 51.1% above the Medical Diagnostics & Research median (#36 of 195)
No single metric tells the full story. See the NSE:SYNGENE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
86GF Score
Get the complete analysis for NSE:SYNGENE
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SYNGENE has been successfully added to your 
